Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia

Autor:	Kunpeng Bu, Mingzhi Xie, Shouming Qin, Xiaoju Chen, Yang Lu, Yongjian Bao
Rok vydání:	2018
Předmět:	Male 0301 basic medicine medicine.medical_specialty Cachexia Lung Neoplasms Side effect Kaplan-Meier Estimate lcsh:RC254-282 Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Quality of life thalidomide Internal medicine lung cancer cachexia medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Cinobufagin Lung cancer Aged business.industry General Medicine Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Bufanolides Thalidomide Treatment Outcome 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Cohort Quality of Life Drug Therapy Combination Female business clinical value medicine.drug
Zdroj:	Journal of Cancer Research and Therapeutics, Vol 14, Iss 1, Pp 226-232 (2018)
ISSN:	0973-1482
DOI:	10.4103/0973-1482.188436
Popis:	Objective: To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin.s Methods: A cohort of 54 patients, who were diagnosed with lung carcinoma, was randomly divided into two groups, a trial group and a control group, respectively. The trial group was given 150 mg/day thalidomide and 2700 mg/day cinobufagin; the control group only received 2,700 mg/day cinobufagin. The therapy lasted for 12 weeks, and the nutritional status, quality of life, survival, and side effects in patients in the two groups were recorded. Results: The nutritional status, quality of life, and survival of patients with lung cancer cachexia in the trial group were significantly improved compared to the control group. The trial group received 150 mg thalidomide, which by contrast reduced the incidence of side effect and increased tolerance. Conclusion: Using thalidomide combined with cinobufagin to treat patients with lung cancer cachexia will significantly improve their nutritional status and quality of life. This therapy is better than that using cinobufagin alone and is well tolerated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f451214a8b7f79a47dc91ffae436aa09 https://doi.org/10.4103/0973-1482.188436 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.